Molecular Partners AG

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - July 21, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021 (the "IPO"); and/or (ii) between June 16, 2021 and April 26, 2022, both dates inclusive (the "Class Period"), of the important...

ROSEN, A Leading Law Firm, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of key preclinical data documenting the unique design and mechanism of action of ensovibep, a clinical stage antiviral DARPin designed and developed by Molecular Partners and Novartis, now fully licensed by Novartis. The study, titled “The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants,” was published today in Nature Biotechnology, and can be accessed through this link.

Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2

Did you lose money on investments in Molecular Partners? If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. ...

MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)

New York, New York--(Newsfile Corp. - July 19, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN) and certain of its officers and directors. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-05925, is on behalf of a class consisting of all persons and entities other...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Molecular Partners AG of Class Action Lawsuit and Upcoming Deadline and Directors - MOLN

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ: MOLN) and certain of its officers, on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents (def

Bronstein, Gewirtz & Grossman, LLC Notifies Molecular Partners AG (MOLN) Investors of Class Action and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Molecular Partners business and prospects, resulting in its stock trading at inflated prices.

INVESTOR NOTICE: Molecular Partners AG Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MOLN

New York, New York--(Newsfile Corp. - July 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021 (the "IPO"); and/or (ii) between June 16, 2021 and April...

MOLN INVESTOR NOTICE: ROSEN, Top Ranked Investor Counsel, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN

SAN DIEGO, July 16, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molecular Partners AG (NASDAQ: MOLN): (a) American Depositary Shares ("ADSs") pursuant and/or traceable to the offering documents issued in connection with Molecular Partners' initial public offering conducted on or about June 16, 2021 (the "IPO"); and/or (b) securities between June 16, 2021 and April 26, 2022, inclusive (the "Class Period") have until September 12, 2022 to seek appointment as lead plaintiff in the Molecular Partners class action lawsuit.  The Molecular Partners class action lawsuit – captioned Freudiger v.

INVESTOR DEADLINE: Molecular Partners AG Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MOLN

SAN DIEGO--(BUSINESS WIRE)---- $MOLN #COVID19--Molecular Partners AG (MOLN) Misled Investors Regarding The Commercial Prospects of its Drug Candidates

Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Molecular Partners AG (MOLN)

NEW YORK , July 15, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN) and certain of its officers, on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about June 16, 2021 (the "IPO"); and/or (b) Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/moln.

Bronstein, Gewirtz & Grossman, LLC Notifies Molecular Partners AG (MOLN) Investors of Class Action and Encourages Investors to Contact the Firm

NEW YORK , July 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021 (the "IPO"); and/or (ii) between June 16, 2021 and April 26, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2022.

MOLN INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ: MOLN) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive, or pur

MOLECULAR PARTNERS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $MOLN #MOLN--Molecular Partners AG (MOLN) Misled Investors Regarding the Commercial Prospects of its Drug Candidates

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Molecular Partners AG (MOLN)

INVESTOR ALERT: Molecular Partners AG Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MOLN

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (ii) between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”). If you wish to serve

EQUITY ALERT: Rosen Law Firm Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOLN

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) --  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will participate in the European Hematology Association (EHA) Conference as well as other conferences in June. In addition, Novartis, the global license owner of ensovibep, will present preclinical data from the anti-SARS-CoV-2 program.

Molecular Partners Announces Participation in Scientific Conferences

NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Partners AG - MOLN

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.

Molecular Partners to Participate in Upcoming Healthcare Investor Conferences

BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Molecular Partners' Chief Executive Officer Patrick Amstutz, Ph.D., has been elected President of the Swiss Biotech Association Board of Directors.

Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association

Molecular Partners AG (NASDAQ: MOLN) shares are trading lower again Thursday on continued weakness after the company recently said its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep. Vas Narasimhan, Novartis' CEO, also.

Why Molecular Partners Shares Are Falling

Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Vas.

Why Molecular Partners Shares Are Getting Hammered

Amgen

Shares of Molecular Partners Inc. MOLN, -36.67% slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91% returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgen's stock was up 0.3% in the premarket on Wednesday.

Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate

Molecular Partners AG's (NASDAQ: MOLN) collaborating partner Amgen Inc (NASDAQ: AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.  MP0310 is a dual-targeted compound targeting both FAP.

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Novartis

Molecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be.

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, is providing an update following comments provided by Novartis during its quarterly earnings call today. In the call, Novartis' CEO, Vas Narasimhan stated that Emergency Use Application (EUA) for ensovibep, which is filed and in review with the U.S. Food and Drug Administration (FDA), may require additional clinical data to be authorized.

News for Molecular Partners AG Stock (MOLN)